chronic myeloproliferative diseases
TRANSCRIPT
![Page 1: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/1.jpg)
Myeloproliferative Neoplasms (MPNs)
Chronic Myeloproliferative Disorders
![Page 2: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/2.jpg)
Definition
• clonal hematologic diseases that arise from a transformation in a hematopoietic stem cell
• main clinical features are– overproduction of one or more of the formed
elements of the blood without significant dysplasia
– Predilection to extramedullary hematopoiesis– Myelofibrosis– Transformation at varying rates to acute leukemia
![Page 3: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/3.jpg)
PVSG Classification
• Chronic myeloid leukemia• Idiopathic myelofibrosis/agnogenic myeloid
metaplasia• Polycythemia vera• Essential or idiopathic thrombocythemia
![Page 4: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/4.jpg)
WHO (2008)classification of MPN
• Chronic myelogenous leukemia [Ph chromosome, t(9;22)(q34;q11), BCR/ABL-positive]
• Chronic neutrophilic leukemia• Polycythemia vera• Primary myelofibrosis• Essential thrombocythemia• Chronic eosinophilic leukemia not otherwise specified• Mastocytosis• Myeloproliferative neoplasms, unclassifiable
![Page 5: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/5.jpg)
Non-leukemic MPNs
• Polycythemia vera (PV)• Essential thrombocytosis (ET)• Primary myelofibrosis
![Page 6: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/6.jpg)
Common clinical features of non-leukemic MPNs (non-MPNs)
• Predominantly affecting middle-aged and older groups
• Insidous, sometimes asymptomatic onset• Panhyperplasia of bone marrow (granulocytic with or
without monocytic elements• Extramedullary hematopoiesis (myeloid metaplasia)
manifested primarily in the spleen and less frequently in the liver
• Bone marrow fibroblastic proliferation and reticulin/collagen formation
![Page 7: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/7.jpg)
• Transition often occurring between these disorders; overlapping manifestations
• Increased propensity for terminating in acute leukemia
• Bone marrow may demonstrate large number of megakaryocytes, sometimes atypical in appearance
• Evidence of platelet dysfunction• Cytogenetic abnormalities
![Page 8: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/8.jpg)
Cardinal Features non-MPNs
![Page 9: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/9.jpg)
![Page 10: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/10.jpg)
Role of JAK2
![Page 11: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/11.jpg)
Role of JAK2
![Page 12: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/12.jpg)
Role of JAK2
![Page 13: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/13.jpg)
Polycythemia Rubra Vera
![Page 14: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/14.jpg)
Polycythemia
Polycythemia – an increase in circulating red blood cells above normal.other term erythrocytosis
![Page 15: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/15.jpg)
Classification of Polycythemia
Elevated HematocritElevated Hematocrit
Absolute polycythemia Relative polycythemiaPrimary Acquired HereditarySecondary
Hct > 50Hgb > 17 g/dL
Hct > 48Hgb > 15 g/dL
Hct > 60 Hct > 55
![Page 16: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/16.jpg)
Classification of Polycythemia
• Absolute (true) polycythemia (RCM)– Primary polycythemia
• Acquired– Polycythemia vera
• Hereditary– Primary familial congenital polycythemia
» Erythropoietin receptor mutation» Unknown gene mutation
– Secondary polycythemia
![Page 17: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/17.jpg)
Secondary polycythemia• Acquired
(Physiologically appropriate increase in EPO)– Hypoxemia
• chronic lung disease• sleep apnea• right-to-left cardiac shunts• high altitude• smoking
– Carboxyhemoglobinemia• smoking• carbon monoxide poisoning
![Page 18: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/18.jpg)
Secondary polycythemia
• Acquired– Autonomous erythropoietin production
• hepatocellular carcinoma• renal cell carcinoma• cerebellar hemangioblastoma• pheochromocytoma• parathyroid carcinoma• meningioma• polycystic kidney disease
![Page 19: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/19.jpg)
Secondary polycythemia
• Acquired– Exogenous erythropoietin administration (“Epo
doping”)– Complex or uncertain etiology
• postrenal transplant (probable abnormal angiotensin II signaling)
• androgen/anabolic steroids
![Page 20: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/20.jpg)
Secondary polycythemia
• Hereditary– High-oxygen affinity hemoglobins– Congenital methemoglobinemia– 2,3-biphosphoglycerate deficiency
![Page 21: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/21.jpg)
Relative (spurious) polycythemia (normal red cell mas)
• Dehydration• Diuretics• Smoking• Gaisböck syndrome (stress polycythemia)
![Page 22: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/22.jpg)
1. Which ONE of the following is NOT a cause of polycythemia?
A. Mutation of JAK 2‐B. chronic renal diseaseC. Congenital heart diseaseD. High-oxygen affinity hemoglobin
![Page 23: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/23.jpg)
Myeloid Metaplasia• splenic infarction• hypersplenism• hypervolemia
Myeloid Metaplasia• splenic infarction• hypersplenism• hypervolemia
IncreasedNucleoproteinTurnover
HyperuricemiaIncreased UrinaryUric acid• Gout• Tophi• Renal stones• Nephropathy
IncreasedNucleoproteinTurnover
HyperuricemiaIncreased UrinaryUric acid• Gout• Tophi• Renal stones• Nephropathy
Hypermetabolism• Weight loss• Diaphoresis• Fatigue• Weakness• Fever
Hypermetabolism• Weight loss• Diaphoresis• Fatigue• Weakness• Fever
ErythemiaHypervolemia• Circulatory overloadErythemia• Thrombosis• Hemorrhage
ErythemiaHypervolemia• Circulatory overloadErythemia• Thrombosis• Hemorrhage
ThrombocythemiaThrombocytopathy• Thrombosis• Hemorrhage
ThrombocythemiaThrombocytopathy• Thrombosis• Hemorrhage
Basophil ProliferationIncreased HistamineTurnover and Release• Pruritus• Gastrointestinal symptoms
Basophil ProliferationIncreased HistamineTurnover and Release• Pruritus• Gastrointestinal symptoms
Acute leukemiaAcute leukemia
Myelofibrosis• Decreased hematopoietic tissueMyelofibrosis• Decreased hematopoietic tissue
OsteosclerosisOsteolysis• Decreased hematopoietic tissue• Pathologic fracture
OsteosclerosisOsteolysis• Decreased hematopoietic tissue• Pathologic fracture
Myelofibrosis• Decreased hematopoietic tissueMyelofibrosis• Decreased hematopoietic tissue
ErythrocyteErythrocyte
MegakaryocyteMegakaryocyte
GranulocyteGranulocyte
FibroblastFibroblast
OsteoblastOsteoclastOsteoblastOsteoclast
Clinical Features
![Page 24: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/24.jpg)
Diagnostic Approach
![Page 25: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/25.jpg)
PVSG criteria for diagnosis of PV
• Category A (Major Criteria)– elevated red cell mass– normal arterial oxygen saturation– splenomegaly
• Category B (Minor Criteria)– leukocytosis– thrombocytosis– elevated leukocyte alkaline phosphatase (score)– increase serum vitamin B12 or vitamin B12-binding protein
PSVG – Polycythemia vera study group: To establis a diagnosis of PV either all 3 major or elevated red mass and normal arterial oxygen saturation plus two minor criteria
![Page 26: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/26.jpg)
![Page 27: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/27.jpg)
General Principles of Therapy
• Reduce the risk of thrombosis by normalizing hematocrit to ≤45% in males and ≤ 42% females
• Use of aspirin• Chemotherapy
– hydroxyurea– anagrelide– interferon (IFN) -α
![Page 28: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/28.jpg)
Which ONE of these statements is TRUE about pseudo (stress) polycythaemia?
A. It is caused by a raised red cell massB. It is associated with a large spleenC. It is treated with hydroxyureaD. It is most common in young male adults
![Page 29: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/29.jpg)
Primary Myelofibrosis
agnogenic myeloid metaplasiamyelofibrosis with myeloid
metaplasia
![Page 30: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/30.jpg)
Definition
• a chronic hematologic neoplasm characterized by– splenomegaly– leukoerythroblastosis– teardrop poikilocytosis– marrow fibrosis– neoangiogenesis– extramedullary hematopoiesis
![Page 31: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/31.jpg)
Clinical features
• An insidious onset in older people is usual with symptoms of anemia.
• Symptoms resulting from massive splenomegaly (e.g. abdominal discomfort, pain or indigestion) are frequent; splenomegaly is the main physical finding
![Page 32: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/32.jpg)
Clinical features
• Hypermetabolic symptoms such as loss of weight, anorexia, fever and night sweats are common.
• Bleeding problems, bone pain or gout occur in a minority of patients.
• Transformation to acute leukemia in 10 – 20 % of cases
![Page 33: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/33.jpg)
Laboratory features
• Anemia is usual but a normal or increased hemoglobin level may be found in some patients.
![Page 34: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/34.jpg)
Laboratory features
• The white cell and platelet counts are frequently high at the time of presentation. Later in the disease leucopenia and thrombocytopenia are common.
• A leucoerythroblastic blood film is found. The red cells show characteristic 'tear-drop' poikilocytes
![Page 35: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/35.jpg)
![Page 36: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/36.jpg)
Laboratory features
• Bone marrow is usually unobtainable by aspiration. Trephine biopsy shows a fibrotic hypercellular marrow. – Increased meg-akaryocytes are frequently seen. – In 10% of cases there is increased bone formation
with increased bone density on X-ray.
![Page 37: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/37.jpg)
![Page 38: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/38.jpg)
Laboratory features
• JAK2 kinase is mutated in approximately 50% of cases.
• High serum urate and LDH levels reflect the increased but largely ineffective turnover of hemopoietic cells.
![Page 39: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/39.jpg)
![Page 40: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/40.jpg)
Which ONE of the following is NOT a typical feature of primary myelofibrosis?
• A It causes a leuko erythroblastic blood film‐• B It may be associated with a raised platelet
count• C Normal serum lactate dehydrogenase level• D It may cause massive splenomegaly
![Page 41: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/41.jpg)
Treatment
• usually palliative and aimed at reducing the effects of anemia and splenomegaly– Blood transfusions and regular folic acid therapy
are used in severely anemic patients.– Hydroxyurea may help to reduce splenomegaly
and hypermetabolic symptoms.– Trials of thalidomide, lenalidomide, azacytidine
and histone deacetylase inhibitors are in progress. – JAK inhibitors (clinical trial)
![Page 42: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/42.jpg)
Prognosis
• The median survival is less than 5 years and causes of death include heart failure, infection and leukemic transformation.
![Page 43: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/43.jpg)
Differential Diagnosis of Myelofibrosis
• Chronic IMF/agnogenic myeloid metaplasia• Other chronic myeloproliferative disorders• Infiltrative disorders/secondary causes of myelofibrosis
– metastatic carcinoma– granulomatous disorders (e.g. Tb, sarcoidosis,
histoplasmosis• Hematologic malignancies
– acute leukemia– hairy cell leukemia– myelodysplastic syndrome– non Hodgkin lymphoma
![Page 44: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/44.jpg)
Essential Thrombocytosis(ET)
Essential ThrombocythemiaIdiopathic thrombocythemiaPrimary Thrombocythemia
Primary Hemorrhagic Thrombocythemia
![Page 45: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/45.jpg)
Major Causes of ThrombocytosisMajor Causes of Thrombocytosis
Reactive Thrombocytosis(Secondary)
Reactive Thrombocytosis(Secondary)
Familial ThrombocytosisFamilial Thrombocytosis Clonal ThrombocytosisClonal Thrombocytosis
![Page 46: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/46.jpg)
Regulation of Platelet Production
![Page 47: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/47.jpg)
PVSG diagnostic criteria for ET• Platelet count > 600 X 109/L• Megakaryocytic hyperplasia• Absence of identifiable causes of reactive thrombocytosis• Absence of Philadelphia chromosome• Hemoglobin no higher than 13 g/dL or normal red cell mass• Absence of significant marrow fibrosis• Presence of stainable marrow iron or failure of iron trial• Splenomegaly
![Page 48: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/48.jpg)
Peripheral blood smear and bone marrow findings in essential thrombocytosis
![Page 49: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/49.jpg)
Causes of Secondary (Reactive) Thrombocytosis
• Transient processes– Acute blood loss– Recovery (“rebound”) from thrombocytopenia– Acute infection or infammation– Response to exercise
• Sustained processes– Iron deficiency– Hemolytic anemia– Asplenia– Cancer– Chronic inflammatory or infectious diseases– Drug reactions
![Page 51: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/51.jpg)
![Page 52: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/52.jpg)
• Which ONE of the following does NOT cause a raised platelet count?
• A Hemorrhage• B Chronic myeloid leukaemia• C Mutation of JAK 2‐• D Aplastic anemia
![Page 53: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/53.jpg)
5. What is the approximate frequency of the Val617Phe mutation in JAK2 in myeloproliferative neoplasms?
A. 99% in polycythaemia vera (PV) and 50% in essential thrombocythaemia (ET) and primary myelofibrosis (PM)
B. Approximately 50% in PV, ET and PMC. 50% in PV and 25% in ET and PMD. 90% in PV, rare in ET and PM
![Page 54: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/54.jpg)
Mastocytosis
• Mastocytosis is a clonal neoplastic proliferation of mast cells that accumulate in one or more organ systems.
![Page 55: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/55.jpg)
Mastocytosis
• Mast cells (tissue basophils) are derived from hemopoietic stem cells. Mature cells survive for months or years in vascular tissues and most organs.
• Systemic mastocytosis is a clonal myeloproliferative disorder involving usually the bone marrow, heart, spleen, lymph nodes and skin.
![Page 56: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/56.jpg)
Mastocytosis
• The somatic KIT mutation Asp816Val is detected in the majority of patients and may be partly responsible for autonomous growth and enhanced survival of the neoplastic mast cells.
• In many patients this mutation is also detected in other hmopoietic cells.
![Page 57: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/57.jpg)
Mastocytosis
• Symptoms are related to histamine and prostaglandin release and include flushing, pruritus, abdominal pain and bronchospasm.
![Page 58: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/58.jpg)
Mastocytosis
• Serum tryptase is increased and can be used to monitor treatment.
• Interferon, chlorodeoxyadenos-ine and tyrosine kinase inhibitors can be helpful.
![Page 59: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/59.jpg)
Mastocytosis
• In many patients the disease runs a chronic indolent course.
• In others an aggressive course may be associated with acute myeloid leukemia, mast cell leukemia or other hemopoietic proliferative or dysplastic condition
![Page 60: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/60.jpg)
![Page 61: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/61.jpg)
Chronic Myelogenous Leukemia
Chronic Myeloid LeukemiaChronic Granulocytic Leukemia
![Page 62: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/62.jpg)
Epidemiology
• Accounts for 15% of adult leukemias• Incidence of 1-2 cases per 100 000 population• Male-to-female ratio of 1.3 to 1• Incidence increases with age• Median age at presentation is 45 to 55 years
![Page 63: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/63.jpg)
Definition• Chronic myeloid leukemia (CML) is a pluripotent stem
cell disease characterized by:– anemia– extreme blood granulocytosis and granulocytic immaturity– basophilia– thrombocytosis – splenogemaly– reciprocal translocation between chromosomes 9 and 22– Inevitable transition from a chronic to an accelerated
phase and on to blast crisis
![Page 64: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/64.jpg)
Philadelphia Chromosome
![Page 65: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/65.jpg)
• The clinical course may be characterized by three separate phases– Chronic phase, which is generally controllable with
chemotherapeutic agents and lasts 2 to 5 years– Accelerated phase, which lasts approximately 6 to
18 months;– Blastic (acute) leukemia phase, which lasts 3 to 4
months and is generally unresponsive to treatment
![Page 66: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/66.jpg)
Risk factors
• DNA topoisomerase II inhibitors• exposure to very high doses of ionizing
radiation
![Page 67: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/67.jpg)
Pathophysiology
Molecular Basis of CML
![Page 69: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/69.jpg)
ABL gene
![Page 70: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/70.jpg)
BCR gene
![Page 71: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/71.jpg)
BCR-ABL gene
![Page 72: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/72.jpg)
Structure of BCR-ABL Fusion Protein
Molecular Consequence of t(9;22)
![Page 73: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/73.jpg)
Mechanism of BCR-ABL mediated malignant transformation
![Page 74: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/74.jpg)
Mechanisms implicated in the pathogenesis of CML
![Page 75: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/75.jpg)
Characteristics of Patients with Chronic Myeloid Leukemia at Presentation
• Clinical findings– Fatigue, anorexia, weight loss– Splenomegaly– Hepatomegaly
• Peripheral-blood findings– Elevated WBC > 25,000/mm3
– Elevated platelet count in 30 to 50% of cases– Basophilia– Reduced leukocyte alkaline phosphatase activity– All stages of granulocyte differentiation visible on
peripheral smear
![Page 76: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/76.jpg)
Faderl, S. et. al. Ann Intern Med 1999;131:207-219
![Page 77: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/77.jpg)
![Page 78: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/78.jpg)
Peripheral blood and bone marrow in CML
![Page 79: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/79.jpg)
Characteristics of Patients with Chronic Myeloid Leukemia at Presentation
• Bone marrow findings– Hypercellularity, reduced fat content– Increased ration of myeloid to erythroid cells– Increased number of megakaryocytes– Blasts and promyelocytes constitute less than 10
percent of all cells
![Page 80: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/80.jpg)
Therapy for CML
![Page 81: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/81.jpg)
Milestone in the Treatment of CML
• 1856 – Arsenicals (Fowler’s solution)• Prior to 1950s – Total-body or splenic
radiation therapy• 1950s – Busulfan• 1972 – Hydroxyurea• 1990s- Interferon α with or without cytosine
arabinoside
![Page 82: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/82.jpg)
Imatinib mesylate
![Page 83: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/83.jpg)
Allogeneic stem cell transplantation
![Page 84: Chronic Myeloproliferative Diseases](https://reader033.vdocuments.net/reader033/viewer/2022061103/540a20bfdab5ca2e688b492b/html5/thumbnails/84.jpg)
Copyright ©2003 AlphaMed Press
Tefferi, A. Oncologist 2003;8:225-231
Figure 1. An operational classification of hematologic malignancies